August 24th, 2020 | 06:58 CEST
BioNTech, CureVac, Valeo Pharma - the license to print money
Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because there is enormous pressure to act from all sides. The sooner vaccines or other products are available, the sooner it will be possible to return to normal everyday life. While two German pharmaceutical companies are investing a lot of money in researching a vaccine, a Canadian competitor is taking an equally exciting and less risky route.
time to read: 2 minutes
|
Author:
Mario Hose
ISIN:
US09075V1026 , NL0015436031 , CA91915B1085
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
The springboard to Canada
Valeo Pharma is a Canadian pharmaceutical company specializing in the licensing, approval and distribution of drugs. Small and medium-sized biotech companies involved in research often have the problem of having to arrange for commercialization once the drug is finished. This is exactly where Valeo Pharma's strength is, because the company is not involved in research and focuses on sales with attractive margins. This eliminates the high costs and risks associated with research and allows management to focus on products that have already been successfully tested. First and foremost, the Canadian home market is the main sales market. Access to physicians is particularly important because they usually prescribe the drugs to patients.
The company already has eight different products in its portfolio and six more in the pipeline. Last week, Valeo Pharma announced that it will increase its equity by CAD 6.00 million as part of a financing deal. If demand is high, the consortium accompanying the measure may increase the volume to up to CAD 6.90 million. In times of the Corona pandemic, a well-filled bank account is helpful to be able to increase, train and equip the staff accordingly. As soon as a partner with a Covid-19 drug knocks on Valeo Pharma's door, the company can enter into negotiations stronger. Valeo Pharma's market capitalization on Friday was just CAD 70.3 million and has corresponding potential due to this comparatively low base.
Research is progressing
BioNTech has already been keeping investors busy for several months. Since the company has joined forces with Pfizer to develop a vaccine against Covid-19, the share price has increased significantly. The company is now valued at more than USD 17.3 billion on the stock exchange. In the past, the experts focused on individual cancer therapies and are now leading the field internationally in the fight against the Corona Pandemic together with several other teams of experts.
In a test involving 30,000 patients, 11,000 people have already received a dose of a drug with a high chance of success. The expectations are already high that a vaccine will be available from BioNTech in the foreseeable future. Nobody can estimate how much potential the stock still has in the short term and what valuation level can be maintained.
Highflyer with chances of success
CureVac is a newcomer to the stock market and already has a market capitalisation of almost USD 12 billion. The German company also belongs to the global elite in research and received financial support from the German government in the race against the pandemic. The EU is already negotiating with CureVac on the possible availability of 225 million vaccine doses. Against this background, high expectations are now included in the company valuation.
The coming days, weeks and months will be exciting. Supplying several billion people with appropriate vaccine doses will be a gigantic task for the industry. In addition, the distribution of vaccine doses is of great economic and political importance. It is therefore not surprising that the company's shares are currently trading heavily.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
